Skip to main content
. 2021 Sep 24;39(44):6520–6528. doi: 10.1016/j.vaccine.2021.09.052

Table 3.

Summary of Primary Efficacy Endpoint.

 Vaccine
 Placebo
Endpoint No. of cases Mean follow-up days Incidence rate
(per 100 person years)		 No. of cases Mean follow-up days Incidence rate
(per 100person years)		 Vaccine Efficacy (%)
Symptomatic confirmed laboratory cases COVID-19 starting 14 days after second injection 7 80.78

3.904		 18 72.08

11.25		 65.30%



Severe 0 0 0 0
–
Critical 0 0 0 0
Death 0 0 0 0